Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference
Gain Therapeutics (Nasdaq: GANX), a clinical-stage biotech company focused on developing next-generation allosteric small molecule therapies, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024.
Gene Mack, Interim CEO and CFO, and Dr. Jonas Hannestad, Chief Medical Officer, will represent Gain Therapeutics at the conference. They will deliver a corporate presentation and engage in one-on-one meetings with potential investors and partners.
This participation provides Gain Therapeutics with an opportunity to showcase its innovative approach to drug discovery and development, potentially attracting investor interest and fostering new collaborations in the biotechnology sector.
Gain Therapeutics (Nasdaq: GANX), una società biotech in fase clinica focalizzata sullo sviluppo di terapie allosteriche a piccole molecole di nuova generazione, ha annunciato la sua partecipazione alla 26ª Conferenza Globale di Investimento Annuale H.C. Wainwright. L'evento è programmato per dal 9 all'11 settembre 2024.
Gene Mack, CEO e CFO ad interim, e Dr. Jonas Hannestad, Chief Medical Officer, rappresenteranno Gain Therapeutics alla conferenza. Effettueranno una presentazione aziendale e parteciperanno a incontri individuali con potenziali investitori e partner.
Questa partecipazione offre a Gain Therapeutics un'opportunità per mettere in mostra il suo approccio innovativo alla scoperta e allo sviluppo di farmaci, attrarre potenziale interesse da parte degli investitori e promuovere nuove collaborazioni nel settore della biotecnologia.
Gain Therapeutics (Nasdaq: GANX), una compañía biotecnológica en etapa clínica centrada en desarrollar terapias de pequeñas moléculas alostéricas de nueva generación, ha anunciado su participación en la 26ª Conferencia Anual de Inversión Global H.C. Wainwright. El evento está programado para del 9 al 11 de septiembre de 2024.
Gene Mack, CEO y CFO interino, y Dr. Jonas Hannestad, Director Médico, representarán a Gain Therapeutics en la conferencia. Realizarán una presentación empresarial y participarán en reuniones uno a uno con posibles inversores y socios.
Esta participación brinda a Gain Therapeutics la oportunidad de mostrar su enfoque innovador en el descubrimiento y desarrollo de fármacos, potencialmente atrayendo el interés de los inversores y fomentando nuevas colaboraciones en el sector biotecnológico.
Gain Therapeutics (Nasdaq: GANX)는 차세대 알로스테릭 소분자 치료제를 개발하는 임상 단계의 생명공학 회사로, H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참가한다고 발표했습니다. 이 행사는 2024년 9월 9일부터 11일까지 예정되어 있습니다.
Gene Mack 임시 CEO 겸 CFO와 Dr. Jonas Hannestad Chief Medical Officer는 컨퍼런스에서 Gain Therapeutics를 대표합니다. 그들은 기업 발표를 진행하고 잠재적인 투자자 및 파트너와 일대일 회의에 참여할 것입니다.
이 참여는 Gain Therapeutics가 약물 발견 및 개발에 대한 혁신적인 접근 방식을 선보일 수 있는 기회를 제공하며, 투자자들의 관심을 끌고 생명공학 분야에서 새로운 협력을 촉진할 가능성을 높입니다.
Gain Therapeutics (Nasdaq: GANX), une société de biotechnologie en phase clinique axée sur le développement de thérapies allostériques à petites molécules de nouvelle génération, a annoncé sa participation à la 26e Conférence Annuelle Mondiale d'Investissement H.C. Wainwright. Cet événement est prévu pour du 9 au 11 septembre 2024.
Gene Mack, PDG et CFO par intérim, et Dr. Jonas Hannestad, Directeur Médical, représenteront Gain Therapeutics lors de la conférence. Ils donneront une présentation de l'entreprise et participeront à des réunions individuelles avec des investisseurs et partenaires potentiels.
Cette participation offre à Gain Therapeutics l'opportunité de mettre en avant son approche innovante en matière de découverte et de développement de médicaments, attirant ainsi l'intérêt des investisseurs et favorisant de nouvelles collaborations dans le secteur de la biotechnologie.
Gain Therapeutics (Nasdaq: GANX), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von next-generation allosterischen kleinen Molekülen konzentriert, hat seine Teilnahme an der 26. jährlichen globalen Investitionskonferenz von H.C. Wainwright angekündigt. Die Veranstaltung ist für 9. bis 11. September 2024 geplant.
Gene Mack, Interim-CEO und CFO, sowie Dr. Jonas Hannestad, Chief Medical Officer, werden Gain Therapeutics auf der Konferenz vertreten. Sie werden eine Unternehmenspräsentation halten und an Einzelgesprächen mit potenziellen Investoren und Partnern teilnehmen.
Diese Teilnahme ermöglicht es Gain Therapeutics, ihren innovativen Ansatz zur Arzneimittelentdeckung und -entwicklung zu präsentieren, was potenziell das Interesse von Investoren wecken und neue Kooperationen im Biotechnologiesektor fördern könnte.
- None.
- None.
BETHESDA, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, Interim CEO and current CFO of Gain, and Jonas Hannestad, M.D., Ph.D., Chief Medical Officer of Gain, will participate in a corporate presentation and one-on-one meetings at the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024.
If you are interested in meeting with the Gain Therapeutics team during the conference, please email meetings@hcwco.com.
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT-02287 for the treatment of Parkinson’s disease with or without a GBA1 mutation, is currently being evaluated in a Phase 1 clinical trial.
Leveraging AI-supported structural biology, proprietary algorithms, and supercomputer-powered physics-based models, the company’s Magellan™ drug discovery platform can identify novel allosteric binding sites on disease-implicated proteins, pinpointing pockets that cannot be found or drugged with current technologies. Its AI and machine-learning tools and virtual screening capabilities leverage the emerging on-demand compound libraries covering vast chemical spaces of over five trillion compounds to identify and select suitable small molecule hits for experimental validation.
Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.
Forward-Looking Statements
This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, risks associated with market conditions and the satisfaction of customary closing conditions related to the offering and uncertainties related to the offerings and the use of proceeds from the offerings. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, please refer to the Company’s prospectus supplement to be filed with the SEC, and the documents incorporated by reference therein, including the Company’s Form 10-K for the year ended December 31, 2023 and Form 10-Q for the quarter ended June 30, 2024. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Apaar Jammu and Chuck Padala
ajammu@gaintherapeutics.com
chuck@lifesciadvisors.com
Media Contacts:
Russo Partners
Nic Johnson and Elio Ambrosio
nic.johnson@russopartnersllc.com
elio.ambrosio@russopartnersllc.com
(212) 845-4242
FAQ
When is Gain Therapeutics (GANX) participating in the H.C. Wainwright Global Investment Conference?
Who will represent Gain Therapeutics (GANX) at the H.C. Wainwright conference?
What activities will Gain Therapeutics (GANX) engage in at the H.C. Wainwright conference?
How can investors arrange meetings with Gain Therapeutics (GANX) at the H.C. Wainwright conference?
